Alamifovir

Drug Profile

Alamifovir

Alternative Names: LY-582563; MCC-478

Latest Information Update: 24 Mar 2009

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Antivirals; Purine nucleotides; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 01 Mar 2005 A study has been added to the Viral infections therapeutic trials section
  • 12 Nov 2002 A preclinical study has been added to the Viral Infections antimicrobial activity section
  • 24 Apr 2002 An animal study has been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top